Caraco Pharmaceutical Laboratories Ltd
Caraco Pharmaceutical Laboratories — Investor Presentation (March 2007)
24 slides from Caraco Pharmaceutical Laboratories's investor presentation, Mar 6, 2007
Slide 1: Caraco Pharmaceutical Laboratories, Ltd.
Caraco Pharmaceutical Laboratories, Ltd.
Slide 2: Safe Harbor
Safe Harbor: This presentation contains forward- looking statements made pursuant to the safe- harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual
Slide 3: Generic Pharmaceutical Industry Overview
Generic Pharmaceutical Industry Overview The Generic Pharmaceutical Industry Primarily Consists of Generic Versions of Brand Pharmaceuticals that have Lost Their Patent Exclusivity or are Products that do not Infringe the Innovator’s Patent U.S. Brand Pharmaceutical Sales for 2005 were $229.5 billio
Slide 4: Company Overview
Caraco Pharmaceutical Laboratories, Ltd. Company Overview Established in 1984, Based in Detroit, MI Caraco Develops, Manufactures, Markets and Distributes Generic and Private-label Pharmaceuticals In 1997, Sun Pharmaceutical Industries Inc. Invested $7.5 Million in Caraco Through a Stock Purchase Ag
Slide 5: Sun Pharmaceutical Industries, Ltd.
Sun Pharmaceutical Industries, Ltd. Established in 1983, Sun Focuses on Specialty Pharmaceuticals and Active Pharmaceutical Ingredients (API’s) Fifth Largest Pharmaceutical Company in India Together, the Technology Transfer and Marketing Agreements Currently Represent 61 Products Awaiting Approval a
Slide 6: What sets us apart?
Caraco Pharmaceutical Laboratories, Ltd. What sets us apart? Size of our Product Portfolio vs. the Size of Company Experienced Management Team Vertically Integrated via Sun API’s Disciplined Management Ability to Service our Customers’ Immediate Needs
Slide 7: Overview: What sets us apart?
Caraco Overview What sets us apart? Diverse Paths of Development Building to fit the Current Environment Improved Customer Mix Removal of Barriers, Execution
Slide 8: Product Market Share Trends
Caraco Pharmaceutical Laboratories, Ltd. Product Market Share Trends Caraco is Currently Marketing 27 Generic Pharmaceuticals and One Brand Product Caraco Launched One Product in the Third Quarter of Fiscal 2007; YTD Caraco has Launched Four Products 14 of the 27 Products are in the Top Three of Gen
Slide 9: Product Market Share Trends
Caraco Pharmaceutical Laboratories, LTD Product Market Share Trends ZONISAMIDE Zonegran ® BACLOFEN Lioresal ® TIZANIDINE Zanaflex ® DIGOXIN Lanoxin ® TRAMADOL W/ APAP Ultracet ® CLONAZEPAM Klonopin ® TRAMADOL Ultram ® PAROMOMYCIN** Humatin ® CHOLINE MAG Trilisate ® GLIPIZIDE Glucotrol ® TICLOPIDINE
Slide 10: Financial Overview
Caraco Pharmaceutical Laboratories, Ltd. Financial Overview Surpassed Record Annual Sales and Net Income Through Nine Months of Fiscal 2007 ($84 Million); Net Sales Growth of 45% Over Corresponding Period of Fiscal 2006 Year-to-Date Gross Profit Margin of Approximately 49%, which is Above the Generi
Slide 11: Annual Historical Results
Caraco Pharmaceutical Laboratories, Ltd. Annual Historical Results (in US $ millions) *Change in fiscal year
Slide 12: Net Sales for Fiscal 2007 (YTD)
Caraco Pharmaceutical Laboratories, Ltd. Net Sales for Fiscal 2007 (YTD) (in US $ millions) * Change in fiscal year
Slide 13: Third Quarter Fiscal 2007 Financial Overview
Third Quarter Fiscal 2007 Financial Overview Third Quarter Net Sales Growth of 51% Gross Profit Margin of 48% Successive Quarterly Growth of 11% over the Second Quarter of 2007
Slide 14: Quarterly Analysis
Caraco Pharmaceutical Laboratories, Ltd. Quarterly Analysis (in US $ millions)
Slide 15: Net Sales by Trade Class
Caraco Pharmaceutical Laboratories, Ltd. Net Sales by Trade Class
Slide 16: Net Sales by Trade Class
Caraco Pharmaceutical Laboratories, Ltd. Net Sales by Trade Class Growth Percentages Chain : 244.7% Dist : 21.5% Whole : 122.9% Mg Care : 50.5% Govt : 15.4%
Slide 17: Third Quarter Fiscal 2007 Highlights
Third Quarter Fiscal 2007 Highlights Signed Two Definitive Agreements Recognized by One of the “Big Three Wholesalers” in US as Best Trade Representative for Companies Under $100 Million in Sales with that Wholesaler Launched Phenytoin ER Filed Two ANDAs with FDA (7 YTD) Bringing Total Products Awai
Slide 18: Product Development Quarterly Filings (ANDAs)
Caraco Pharmaceutical Laboratories, Ltd. Product Development Quarterly Filings (ANDAS) *Includes two tentative FDA approvals
Slide 19: Capacity
Capacity Current Owned Facilities are 114,000 sq ft and Lease Another 67,000 sq ft for Total Footprint of Approximately 180,000 sq ft Need to Build 100,000 - 125,000 sq ft Facility or Move to 250,000 sq. ft cGMP Facility for Complete Company Move Can Expand up to 450,000 sq ft at Current Sites Fisca
Slide 20: Product Litigation
Product Litigation Lexapro – Teva/IVAX Lost First Case, Teva Appealed Decision on November 6, 2006; Possible Upside if Caraco Prevails. Forest was Denied Motion to Transfer its Action Against Caraco to the United States District Court for the District of Delaware; the Litigation will Proceed in East
Slide 21: Drivers Fiscal 2008
Drivers Fiscal 2008 Approvals – Phenytoin ER Pending Approvals Increase / Maintain Share Increase and Close Alternate Development Projects
Slide 22: Drivers Fiscal 2008
Drivers Fiscal 2008 Expand Current Development Streams and Pursue New Opportunities Improve Packaging Continue Staff Improvements and Succession Planning
Slide 23: Summary
Caraco Pharmaceutical Laboratories, Ltd. Summary Well Positioned to Execute Plan We are Built to Fit the Current Competitive Environment Vertical Integration with Sun Allows us to Enjoy Longer Lifecycles and Value on Products that We Market Large Basket of Products Awaiting Approval At FDA
Slide 24: Thank You
CARACO Thank You
Caraco Pharmaceutical Laboratories — Investor Presentation (March 2007) on 6ix